278 related articles for article (PubMed ID: 35717100)
1.
Hemrom A; Tupalli A; Alavi A; Kumar R
PET Clin; 2022 Jul; 17(3):415-430. PubMed ID: 35717100
[TBL] [Abstract][Full Text] [Related]
2. 18F-fluorocholine versus 18F-fluorodeoxyglucose for PET/CT imaging in patients with suspected relapsing or progressive multiple myeloma: a pilot study.
Cassou-Mounat T; Balogova S; Nataf V; Calzada M; Huchet V; Kerrou K; Devaux JY; Mohty M; Talbot JN; Garderet L
Eur J Nucl Med Mol Imaging; 2016 Oct; 43(11):1995-2004. PubMed ID: 27121691
[TBL] [Abstract][Full Text] [Related]
3. Imaging CXCR4 receptors expression for staging multiple myeloma by using
Shekhawat AS; Singh B; Malhotra P; Watts A; Basher R; Kaur H; Hooda M; Radotra BD
Br J Radiol; 2022 Aug; 95(1136):20211272. PubMed ID: 35731811
[TBL] [Abstract][Full Text] [Related]
4. 11C-choline vs. 18F-FDG PET/CT in assessing bone involvement in patients with multiple myeloma.
Nanni C; Zamagni E; Cavo M; Rubello D; Tacchetti P; Pettinato C; Farsad M; Castellucci P; Ambrosini V; Montini GC; Al-Nahhas A; Franchi R; Fanti S
World J Surg Oncol; 2007 Jun; 5():68. PubMed ID: 17584499
[TBL] [Abstract][Full Text] [Related]
5. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
6. Comparison of the diagnostic performance and impact on management of 18F-FDG PET/CT and whole-body MRI in multiple myeloma.
Westerland O; Amlani A; Kelly-Morland C; Fraczek M; Bailey K; Gleeson M; El-Najjar I; Streetly M; Bassett P; Cook GJR; Goh V;
Eur J Nucl Med Mol Imaging; 2021 Jul; 48(8):2558-2565. PubMed ID: 33469686
[TBL] [Abstract][Full Text] [Related]
7. [PET/CT with 18F-fluorodeoxyglucose and 11C-methionine after autologous stem cell transplantation in multiple myeloma patients].
Solovev MV; Mendeleeva LP; Firsova MV; Aslanidi IP; Mukhortova OV; Savchenko VG
Ter Arkh; 2019 Jul; 91(7):75-82. PubMed ID: 32598739
[TBL] [Abstract][Full Text] [Related]
8.
Morales-Lozano MI; Rodriguez-Otero P; Sancho L; Nuñez-Cordoba JM; Prieto E; Marcos-Jubilar M; Rosales JJ; Alfonso A; Guillen EF; San-Miguel J; Garcia-Velloso MJ
Int J Mol Sci; 2022 Aug; 23(17):. PubMed ID: 36077292
[TBL] [Abstract][Full Text] [Related]
9. 18F-FDG PET/CT, 99mTc-MIBI, and MRI in the prediction of outcome of patients with multiple myeloma: a comparative study.
Fonti R; Pace L; Cerchione C; Catalano L; Salvatore B; De Luca S; Pane F; Salvatore M; Del Vecchio S
Clin Nucl Med; 2015 Apr; 40(4):303-8. PubMed ID: 25608167
[TBL] [Abstract][Full Text] [Related]
10. 11C-acetate positron emission tomography is more precise than 18F-fluorodeoxyglucose positron emission tomography in evaluating tumor burden and predicting disease risk of multiple myeloma.
Chen M; Zhu W; Du J; Yang C; Han B; Zhou D; Huo L; Zhuang J
Sci Rep; 2021 Nov; 11(1):22188. PubMed ID: 34773054
[TBL] [Abstract][Full Text] [Related]
11. The potential utility of [
Lan L; Liu H; Wang Y; Deng J; Peng D; Feng Y; Wang L; Chen Y; Qiu L
Eur J Nucl Med Mol Imaging; 2022 Feb; 49(3):963-979. PubMed ID: 34410435
[TBL] [Abstract][Full Text] [Related]
12. Interpretation criteria for FDG PET/CT in multiple myeloma (IMPeTUs): final results. IMPeTUs (Italian myeloma criteria for PET USe).
Nanni C; Versari A; Chauvie S; Bertone E; Bianchi A; Rensi M; Bellò M; Gallamini A; Patriarca F; Gay F; Gamberi B; Ghedini P; Cavo M; Fanti S; Zamagni E
Eur J Nucl Med Mol Imaging; 2018 May; 45(5):712-719. PubMed ID: 29270787
[TBL] [Abstract][Full Text] [Related]
13. Role of
Piccardo A; Trimboli P; Puntoni M; Foppiani L; Treglia G; Naseri M; Bottoni GL; Massollo M; Sola S; Ferrarazzo G; Bruzzone M; Catrambone U; Arlandini A; Paone G; Ceriani L; Cabria M; Giovanella L
Thyroid; 2019 Apr; 29(4):549-556. PubMed ID: 30864903
[TBL] [Abstract][Full Text] [Related]
14. [
Lapa C; Schreder M; Schirbel A; Samnick S; Kortüm KM; Herrmann K; Kropf S; Einsele H; Buck AK; Wester HJ; Knop S; Lückerath K
Theranostics; 2017; 7(1):205-212. PubMed ID: 28042328
[TBL] [Abstract][Full Text] [Related]
15. Comparison of [68Ga]-FAPI PET/CT and [18F]-FDG PET/CT in Multiple Myeloma: Clinical Experience.
Elboga U; Sahin E; Cayirli YB; Okuyan M; Aktas G; Haydaroglu Sahin H; Dogan I; Kus T; Akkurd DM; Cimen U; Mumcu V; Kilbas B; Celen YZ
Tomography; 2022 Feb; 8(1):293-302. PubMed ID: 35202189
[TBL] [Abstract][Full Text] [Related]
16. Prospective comparison of 18-FDG PET/CT and whole-body diffusion-weighted MRI in the assessment of multiple myeloma.
Mesguich C; Hulin C; Latrabe V; Lascaux A; Bordenave L; Hindié E; Marit G
Ann Hematol; 2020 Dec; 99(12):2869-2880. PubMed ID: 32951093
[TBL] [Abstract][Full Text] [Related]
17. Multi-parametric whole-body MRI evaluation discerns vital from non-vital multiple myeloma lesions as validated by
Heidemeier A; Schloetelburg W; Thurner A; Metz C; Heidemeier H; Rasche L; Martin Kortuem K; Boeckle D; Weiland E; Benkert T; Nickel D; Werner R; Buck AK; Bley TA
Eur J Radiol; 2022 Oct; 155():110493. PubMed ID: 36027759
[TBL] [Abstract][Full Text] [Related]
18. Comparison of meta-analyses among elastosonography (ES) and positron emission tomography/computed tomography (PET/CT) imaging techniques in the application of prostate cancer diagnosis.
Ouyang Q; Duan Z; Lei J; Jiao G
Tumour Biol; 2016 Mar; 37(3):2999-3007. PubMed ID: 26415734
[TBL] [Abstract][Full Text] [Related]
19. PET/CT studies of multiple myeloma using (18) F-FDG and (18) F-NaF: comparison of distribution patterns and tracers' pharmacokinetics.
Sachpekidis C; Goldschmidt H; Hose D; Pan L; Cheng C; Kopka K; Haberkorn U; Dimitrakopoulou-Strauss A
Eur J Nucl Med Mol Imaging; 2014 Jul; 41(7):1343-53. PubMed ID: 24562650
[TBL] [Abstract][Full Text] [Related]
20. Chemokine receptor-4 targeted PET/CT with
Pan Q; Cao X; Luo Y; Li J; Feng J; Li F
Eur J Nucl Med Mol Imaging; 2020 Mar; 47(3):537-546. PubMed ID: 31776631
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]